Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03728933 · ClinicalTrials.gov registry record · Phase 3
A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause
A Phase 3 study, sponsored by UCB Biopharma SRL.
- Terminated
- Registry status
- Phase 3
- Development phase
- 23
- Enrollment target
NCT03728933 is a Phase 3 study that was terminated before completion, run by UCB Biopharma SRL. The registered enrollment target is 23 participants.
The verdict
NCT03728933, a Phase 3 study, was terminated before completion, sponsored by UCB Biopharma SRL.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the efficacy of rotigotine against placebo in adolescent subjects with idiopathic Restless Legs Syndrome (RLS) over a 12-week maintenance period and to investigate the safety and tolerability of rotigotine in adolescent subjects with idiopathic RLS.
Interventions
- DRUG Placebo
- DRUG Rotigotine 1 milligram/24 hours
- DRUG Rotigotine 2 milligram/24 hours
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-12-20 |
| Est. Completion | 2022-07-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03728933
The ClinicalTrials.gov registry entry for NCT03728933 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03728933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03728933 about?
NCT03728933 is a clinical study titled "A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause". The purpose of this study is to demonstrate the efficacy of rotigotine against placebo in adolescent subjects with idiopathic Restless Legs Syndrome (RLS) over a 12-week maintenance period and to investigate the safety and tolerability of rotigotine in adolescent subjects with idiopathic RLS.
What is the current status of trial NCT03728933?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 23 participants. The study started on 2018-12-20. Estimated completion is 2022-07-25.
What interventions are being tested in trial NCT03728933?
The interventions under investigation include: Placebo (DRUG), Rotigotine 1 milligram/24 hours (DRUG), Rotigotine 2 milligram/24 hours (DRUG).
Who is sponsoring clinical trial NCT03728933?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.